---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000012"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T06:07:13.073697+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q4 adj EPS $0.94, rev $398M; FY2023 guidance rev $1.60-1.62B, adj EPS $3.43-3.51

## Summary
- Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.
- Full-year 2022 revenues $1,557.7M (+1.0% reported, +4.2% organic); GAAP EPS $2.16, adj EPS $3.36.
- FY2023 guidance: revenues $1,602M-$1,620M (organic growth 4.0%-5.2%), adj EPS $3.43-$3.51.
- Entered $150M accelerated share repurchase agreement with Goldman Sachs, expected to complete in H1 2023.
- Codman Specialty Surgical organic growth 1.8%; Tissue Technologies organic growth 5.0% in Q4.

## SEC filing metadata
- accession: 0000917520-23-000012
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/iart-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000012
- JSON: https://secwatch.observer/filing/0000917520-23-000012.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000012.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported Q4 2022 results: revenue $398.0 million, net income $52.9 million, EPS $0.63.
  - Period: Q4 2022
  - Revenue: $398.0 million
  - Net income: $52.9 million
  - EPS: $0.63
  - Result: reported results
  source text: Total reported revenues for the fourth quarter were $398.0 million, a decrease of 1.8% from the fourth quarter of 2021. Fourth quarter organic revenues increased 2.9% over the prior year. The Company reported GAAP net income of $52.9 million, or $0.63 per diluted share, in the fourth quarter of 2022, compared to GAAP net income of $45.4 million, or $0.53 per diluted share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2023 results: revenue $1,602 million to $1,620 million. Guidance initiated.
  - Period: FY2023
  - Revenue: $1,602 million to $1,620 million
  - Guidance: initiated
  - Result: guidance update
  source text: For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, representing reported growth of approximately 2.9% to 4.0% and organic growth in the range of 4.0% to 5.2%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2022 results: revenue $1,557.7 million, net income $180.6 million, EPS $2.16.
  - Period: FY2022
  - Revenue: $1,557.7 million
  - Net income: $180.6 million
  - EPS: $2.16
  - Result: reported results
  source text: to $0.53 in the fourth quarter 2021. • Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Full-Year 2022 • Reported revenues were 1,557.7 million representing an increase of 1.0% on a reported basis and an increase of 4.2% on an organic basis compared to full-year 2021. • GAAP earnings per diluted share wer e $2.16,
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.